Latest Pharma and Biotech News
Biotechnology
10 July 2025 US pharma major AbbVie and IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation today announced an exclusive licensing agreement for IGI's lead investigational asset, ISB 2001, developed using IGI's proprietary BEAT protein platform, for oncology and autoimmune diseases.
Today's issue
Refine Search
Pharmaceutical
A new analysis from US data analytics firm Phesi has raised concerns about the viability of ongoing Phase III trials in atopic dermatitis (AD), pointing to a rising risk of failure driven by flawed trial design and overreliance on saturated investigator sites. 9 July 2025
Pharmaceutical
Danish drugmaker Novo Nordisk has filed for European approval of a higher-dose version of its obesity treatment Wegovy (semaglutide), aiming to expand options for patients who need stronger support for weight loss. 9 July 2025
Biotechnology
Radiopharmaceutical biotech Actithera today announced the close of an oversubscribed $75.5 million Series A financing round. 9 July 2025
Pharmaceutical
Donald Trump has escalated his warnings to the pharmaceutical industry with a pledge to introduce import tariffs as high as 200% on drugs produced outside the USA. The US president said companies would be granted a grace period of up to 18 months before the measure takes effect. 9 July 2025
Biotechnology
US oncology-focused biotech Crescent Biopharma has appointed Jan Pinkas as chief scientific officer (CSO). 8 July 2025
Biotechnology
Debra Barker has been named chief medical officer (CMO) at Centauri Therapeutics, a UK immunotherapy company with a proprietary platform technology applicable across a wide range of therapeutic indications. 8 July 2025
Biotechnology
San Francisco, USA-based biotech Centivax, which is developing durable, universal vaccines, today announced the close of a $45 million Series A led by Steve Jurvetson’s Future Ventures, with participation from NFX, BOLD Capital, Base4, Kendall Capital Partners, Amplify Bio, and existing investors. 8 July 2025
Biotechnology
Diagonal Therapeutics, a US biotech focused on correcting dysregulated signaling with clustering antibodies that address the underlying cause of intractable genetic diseases, has announced the appointment of John Lee as chief medical officer (CMO). 8 July 2025
Pharmaceutical
Switzerland-based MetP Pharma, pioneer in nose-to-brain drug delivery for nearly two decades, announced new data highlighting the advantages of its proprietary MetP Technology in delivering neuroactive peptides such as semaglutide directly to the brain via the intranasal route. 8 July 2025
Biosimilars
The US subsidiary of South Korea-based Celltrion today announced that Stoboclo (denosumab-bmwo) and Osenvelt (denosumab-bmwo), biosimilars referencing US biotech major Amgen’s (Nasdaq: AMGN) denosumab brands Prolia and Xgeva, had been launched in the USA. 8 July 2025
Biotechnology
US CAR-T focused biotech CARGO Therapeutics today announced that it has entered into a definitive merger agreement with Concentra Biosciences, initially worth roughly $200 million. The news sent CARGO’s stock up as much as 9.6% to $4.81 in pre-market activity. 8 July 2025
Biotechnology
Having appointed Renée Aguiar-Lucander as its chief executive in April and Maria Törnsén as chief operating officer a month later, Hansa Biopharma has announced the appointment of a chief medical officer (CMO). 8 July 2025
Biotechnology
US biotech Cogent Biosciences closed Monday’s trading 23% higher, following the company’s announcement of positive top-line results from the registration-directed part two of the SUMMIT clinical trial of bezuclastinib in patients with non-advanced systemic mastocytosis (NonAdvSM). 8 July 2025
Pharmaceutical
Swiss pharma giant Novartis today announced Coartem (artemether-lumefantrine) Baby has been approved by Swissmedic as the first malaria medicine for newborns and young infants. 8 July 2025
Pharmaceutical
Shares in Japanese drugmaker Otsuka Holdings closed nearly 2% lower Tuesday, after disappointing clinical trial results from one of its subsidiaries. 8 July 2025
Biotechnology
French biotech Nanobiotix’ shares were up nearly 7% at 4.44 euros in early trading, after the company announced two important developments that aim to reinforce the global positioning of potential first-in-class radioenhancer JNJ-1900 (NBTXR3), which is licensed by Janssen Pharmaceutica, a Johnson & Johnson subsidiary. 8 July 2025
Biotechnology
Shares of US clinical-stage biotech Apogee Therapeutic closed down 17.3% at $39.24 yesterday, despite announcing positive 16-week data from Part A of the Phase II APEX clinical trial of APG777, a potential best-in-class anti-interleukin (IL)-13 antibody, in patients with moderate-to-severe atopic dermatitis (AD). 8 July 2025
Pharmaceutical
Eli Lilly led the way in pharma M&A during June. 7 July 2025
Biotechnology
Japanese drugmaker Chugai Pharmaceutical has entered into a joint research and license agreement to develop novel therapies for age-related diseases with Singapore-based biotech Gero. 7 July 2025
Biotechnology
The GPRC5D-directed therapies market is witnessing robust growth, driven by high unmet need in relapsed/refractory multiple myeloma, according to a report on the field by DelveInsight. 7 July 2025
All news
Pharmaceutical
CSL Seqirus, a subsidiary of Australia’s CSL Limited, said it has commenced shipping its differentiated portfolio of influenza vaccines for the 2025/26 US season. 11 July 2025
Biotechnology
US biotech Capricor Therapeutics today revealed receipt of a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA) regarding its Biologics License Application (BLA) for deramiocel, the company’s lead cell therapy candidate for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD). 11 July 2025
Pharmaceutical
At its July meeting, the European Medicines Agency’s pharmacovigilance committee (PRAC) completed its review of French specialty vaccine maker Valneva Ixchiq (chikungunya virus vaccine, a live attenuated chikungunya vaccine, following reports of serious side effects. 11 July 2025
Biotechnology
The National Institute for Health and Care Excellence (NICE) has published final guidance recommending Eli Lilly’s Omvoh (mirikizumab) for use on the National Health Service (NHS) in England and Wales as an option for moderately to severely active Crohn’s disease in adults. 11 July 2025
Biotechnology
California-based Renasant Bio announced its launch to advance next-generation disease-modifying treatments for autosomal dominant polycystic kidney disease (ADPKD), the leading genetic cause of end-stage renal failure. 11 July 2025
Pharmaceutical
Nuclidium, a radiopharma company developing a proprietary copper-based theranostic platform, has announced the successful closing of its Series B financing round, raising 79 million Swiss francs ($99 million). 11 July 2025
Biotechnology
BrainXell, a US biotechnology company developing iPSC-based CNS disease models and regenerative cell therapies, has announced the appointment of Katherine Vega Stultz as its new chief executive and board director. 11 July 2025
Pharmaceutical
Sino-American drug discovery firms TandemAI and Perpetual Medicines have merged. 11 July 2025
Biotechnology
Chinese cell therapy developer NK CellTech has raised nearly 100 million renminbi ($14 million) in an extended series A+++ round to support the clinical development of its flagship NK cell therapies and broaden its pipeline. 11 July 2025
Biotechnology
Sino-American biopharma Ascentage Pharma announced that its proprietary novel Bcl-2 selective inhibitor lisaftoclax (APG-2575) has been approved by China’s National Medical Products Administration (NMPA). 11 July 2025
Pharmaceutical
Lewy body dementia (LBD) remains one of the most overlooked and complex neurodegenerative conditions, but momentum is building around a small group of experimental therapies, according to new research from DelveInsight. 11 July 2025
Biotechnology
The US Food and Drug Administration (FDA) has approved US mRNA specialist Moderna supplemental Biologics License Application (sBLA) for Spikevax, the company's COVID-19 vaccine, in children six months through 11 years of age who are at increased risk for COVID-19 disease. 11 July 2025
Biotechnology
Shares in US biotech Ultragenyx Pharmaceutical and its UK-based partner Mereo BioPharma tumbled after the companies confirmed their pivotal trial in osteogenesis imperfecta (OI) would not be stopped early, defying investor hopes for a quicker path to approval. 11 July 2025
Biotechnology
French biotech Osivax has published results from a Phase IIa trial showing that its lead candidate OVX836, a broad-spectrum influenza vaccine, demonstrated a strong safety profile and immune response when administered alongside a conventional flu shot. 10 July 2025
Biotechnology
China-based biotech Biocytogen has signed a global licensing agreement with oncology-focused BeOne Medicines, handing over rights to multiple fully human antibodies discovered through its proprietary RenMice platform. 10 July 2025
Pharmaceutical
The US Food and Drug Administration (FDA) has taken the radical move of publishing more than 200 decision letters, known as complete response letters (CRLs). 10 July 2025
Pharmaceutical
The US Food and Drug Administration (FDA) has accepted for review Merck & Co’s New Drug Application (NDA) for doravirine/islatravir (DOR/ISL), an investigational, once-daily, oral, two-drug regimen for adults with HIV-1 infection that is virologically suppressed on antiretroviral therapy. 10 July 2025
Biotechnology
US late-stage oncology-focused Revolution Medicines and Iambic Therapeutics, which is developing novel medicines using its AI-driven discovery and development platform, today announced a technology and research collaboration to pursue novel drug candidates using Iambic’s leading AI models. 10 July 2025
Biotechnology
The European Commission has approved Tevimbra (tislelizumab), alongside gemcitabine and cisplatin, for the first-line treatment of adults with metastatic or recurrent nasopharyngeal carcinoma (NPC), not amenable to curative surgery or radiotherapy. 10 July 2025
Biotechnology
US pharma major AbbVie and IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation today announced an exclusive licensing agreement for IGI's lead investigational asset, ISB 2001, developed using IGI's proprietary BEAT protein platform, for oncology and autoimmune diseases. 10 July 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze